About the information that Cuu Long Pharmaceutical Joint Stock Company (DCL) was terminated the drug supply contract with Nghe An Oncology Hospital, the company’s representative had an immediate response to the incident.
Facing this information, a representative of Cuu Long Pharmaceutical Joint Stock Company said: First of all, we regret that although the company has won the bid for Bevacibin 500mg product (active ingredient Capecitabin, film-coated tablets, registration number VN3- 225-19) at a lower price than similar products, we could not provide drugs for hospitals and patients. This comes from objective factors that DCL does not want to happen. Due to the Covid-19 epidemic that has disrupted the global production and supply chain, DCL’s supplier in Europe was also stopped working, so there is no output to supply to DCL. Therefore, we have worked and discussed many times with the supplier, and also informed the Nghe An Oncology Hospital.
Currently, for other key cancer drugs of DCL, Benivatib with 100mg and 400mg content, meeting European quality is winning major contracts of major hospitals such as National Institute Of Hematology & Blood Transfusion, Hanoi Oncology Hospital, Hospital 175, Blood Transfusion Hematology Hospital, Ho Chi Minh City, Nguyen Trai Hospital, Binh Dan Hospital, etc., the total winning value is nearly 200 billion VND. Since DCL participated in the bidding to supply this cancer drug to hospitals, it has helped patients reduce treatment costs and helped the state save the health insurance agency’s payment budget. DCL’s cancer drug patents also promise to bring in millions of dollars in sales for 2022 and beyond.
During 45 years of operation, DCL has always been highly appreciated by patients, employees and partners. Since 2015, with the comprehensive investment of the parent company, F.I.T Group Joint Stock Company, DCL has had a clear change when building a strong operating foundation from management, production operation, business… As a result, in recent years, despite many fluctuations and difficulties in the pharmaceutical industry, DCL still recorded positive business results, creating a solid foundation for a breakthrough in the coming time. In particular, DCL’s business results in the first 6 months of the year were estimated at more than VND 433 billion, an increase of VND 67 billion compared to the same period last year, and profit before tax was estimated at VND 50 billion.
In May 2022, DCL was also honored to receive the award “Top 10 Vietnam Leading Brands 2022”, contributing to further affirming DCL’s position and reputation in the pharmaceutical field. With business strategies being promoted, DCL’s product lines promise to continue to contribute to protecting and improving the quality of life of Vietnamese families in the coming time.
